Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Oscar Alfredo, Castillo Trujillo"'
Autor:
Maria Carmen Riesco-Martinez, Jaume Capdevila, Vicente Alonso, Paula Jimenez-Fonseca, Alex Teule, Enrique Grande, Isabel Sevilla, Marta Benavent, Teresa Alonso-Gordoa, Ana Custodio, Beatriz Anton-Pascual, Jorge Hernando, Eduardo Polo, Oscar Alfredo Castillo-Trujillo, Arantza Lamas-Paz, Ana Teijo, Yolanda Rodriguez-Gil, Beatriz Soldevilla, Rocio Garcia-Carbonero
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-10 (2024)
Abstract The prognosis of patients with advanced high-grade (G3) digestive neuroendocrine neoplasms (NENs) is rather poor. The addition of immune checkpoint inhibition to platinum-based chemotherapy may improve survival. NICE-NEC (NCT03980925) is a s
Externí odkaz:
https://doaj.org/article/6981a3198f934da4bebd41d0dfe4b108
Autor:
Adán Rodríguez-Gonzalez, Alberto Carmona-Bayonas, Raquel Hernandez San Gil, Patricia Cruz-Castellanos, Mónica Antoñanzas-Basa, David Lorente-Estelles, María Jose Corral, Manuel González-Moya, Oscar Alfredo Castillo-Trujillo, Emilio Esteban, Paula Jiménez-Fonseca, Caterina Calderon
Publikováno v:
Clinical and Translational Oncology.
Autor:
Manuel Valladares-Ayerbes, Pilar Garcia-Alfonso, Jorge Muñoz Luengo, Paola Patricia Pimentel Caceres, Oscar Alfredo Castillo Trujillo, Rosario Vidal-Tocino, Marta Llanos, Beatriz Llorente Ayala, Maria Luisa Limon Miron, Antonieta Salud, Luis Cirera Nogueras, Rocio Garcia-Carbonero, Maria Jose Safont, Esther Falco Ferrer, Jorge Aparicio, Maria Angeles Vicente Conesa, Carmen Guillén-Ponce, Paula Garcia-Teijido, Maria Begoña Medina Magan, Isabel Busquier, Mercedes Salgado, Ariadna Lloansí Vila
Publikováno v:
Cancers; Volume 14; Issue 24; Pages: 6075
The serial analysis of cell-free DNA (cfDNA) enables minimally invasive monitoring of tumor evolution, providing continuous genetic information. PERSEIDA was an observational, prospective study assessing the cfDNA RAS (KRAS/NRAS) mutational status ev
Autor:
Manuel, Valladares-Ayerbes, Pilar, Garcia-Alfonso, Jorge, Muñoz Luengo, Paola Patricia, Pimentel Caceres, Oscar Alfredo, Castillo Trujillo, Rosario, Vidal-Tocino, Marta, Llanos, Beatriz, Llorente Ayala, Maria Luisa, Limon Miron, Antonieta, Salud, Luis, Cirera Nogueras, Rocio, Garcia-Carbonero, Maria Jose, Safont, Esther, Falco Ferrer, Jorge, Aparicio, Maria Angeles, Vicente Conesa, Carmen, Guillén-Ponce, Paula, Garcia-Teijido, Maria Begoña, Medina Magan, Isabel, Busquier, Mercedes, Salgado, Ariadna, Lloansí Vila
Publikováno v:
Cancers. 14(24)
The serial analysis of cell-free DNA (cfDNA) enables minimally invasive monitoring of tumor evolution, providing continuous genetic information. PERSEIDA was an observational, prospective study assessing the cfDNA
Optimizing the febrile neutropenia care process in cancer patients in a third level Spanish hospital
Autor:
Emilio Esteban, Carlos Alvarez Fernandez, Jorge del Río Fernández, Maria Muniz Castrillo, Marta Izquierdo Manuel, Maria Pilar Solis-Hernandez, Luka Mihic Góngora, Sara Fernandez Arrojo, Noemi Villanueva, Debora Corina Contreras Toledo, Sena Valcárcel González, Paula Jiménez Fonseca, Clara Iglesias Gomez, Yolanda Fernandez Perez, Oscar Alfredo Castillo Trujillo, Alfonso Revuelta, David Gomez, Isabel Palacio Vázquez, Juan Luis García Llano
Publikováno v:
Journal of Clinical Oncology. 38:e14034-e14034
e14034 Background: Cancer patients under cytotoxic treatment with fever used to have an average time of antibiotics administration of 11h (median 3h43min) when admitted and identified at the Emergency Room Service in the third level Central Universit
Autor:
Paula Jiménez-Fonseca, Oscar Alfredo Castillo Trujillo, Federico Longo, Mercedes Rodríguez Garrote, Alfredo Carrato, Juan José Serrano Domingo, Jaime Portela, Alberto San Juan del Moral, Enrique Aranda, Juana María Cano, Pablo Reguera Puertas, Elena Corral de la Fuente, Marta Izquierdo Manuel, Roberto Martin Huertas
Publikováno v:
Journal of Clinical Oncology. 37:e15707-e15707
e15707 Background: Advanced pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with a five-year overall survival (OS) of less than 5%. Folfirinox and Nab-Paclitaxel plus Gemcitabine (NabPacGem) are the most active treatments in the fi